Management of Refractory Chronic Cough and Emerging Therapies in 2025
DOI:
https://doi.org/10.58931/crt.2025.1211Abstract
Chronic cough, defined as cough lasting for more than 8 weeks, affects approximately 10% of adults globally, with prevalence reaching as high as 16% in Canada. Cough is the leading cause of ambulatory and primary care visits and one of the most common reasons for referral to secondary care. Patients with chronic cough experience a median of 500 coughs per day, which significantly impairs their quality of life. This high frequency of coughing leads to distressing physical, psychological, and social consequences, such as urinary incontinence, exhaustion, sleep disturbances, fatigue, anxiety, frustration, embarrassment, and social isolation, especially in the post-COVID era.
References
Song W-J, Chang Y-S, Faruqi S, Kim J-Y, Kang M-G, Kim S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. 2015;45(5):1479–1481. doi:10.1183/09031936.00218714
Satia I, Mayhew AJ, Sohel N, Kurmi O, Killian KJ, O’Byrne PM, et al. Prevalence, incidence and characteristics of chronic cough among adults from the Canadian Longitudinal Study on Aging. ERJ Open Res. 2021;7(2):00160-2021. doi:10.1183/23120541.00160-2021
Finley CR, Chan DS, Garrison S, Korownyk C, Kolber MR, Campbell S, et al. What are the most common conditions in primary care? Systematic review. Can Fam Physician. 2018;64(11):832–840.
Dicpinigaitis PV, Birring SS, Blaiss M, McGarvey LP, Morice AH, Pavord ID, et al. Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. Ann Allergy Asthma Immunol. 2023;130(1):60–66. doi:10.1016/j.anai.2022.05.003
Parker SM, Smith JA, Birring SS, Chamberlain-Mitchell S, Gruffydd-Jones K, Haines J, et al. British Thoracic Society Clinical Statement on chronic cough in adults. Thorax. 2023;78(Suppl 6):s3–s19. doi:10.1136/thorax-2023-220592
Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1). doi:10.1183/13993003.01136-2019
Smith JA, Satia I, Badri H, Marsden P. Mini-review: hypertussivity and allotussivity in chronic cough endotypes. Neurosci Lett. 2023;792:136934. doi:10.1016/j.neulet.2022.136934
Hilton E, Marsden P, Thurston A, Kennedy S, Decalmer S, Smith JA. Clinical features of the urge-to-cough in patients with chronic cough. Respir Med. 2015;109(6):701–707. doi:10.1016/j.rmed.2015.03.011
Hilton EC, Baverel PG, Woodcock A, Van Der Graaf PH, Smith JA. Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point. J Allergy Clin Immunol. 2013;132(4):847–855.e555. doi:10.1016/j.jaci.2013.04.042
Satia I, Hassan W, McGarvey L, Birring SS. The clinical approach to chronic cough. J Allergy Clin Immunol Pract. 2025;13(3):454–466. doi:10.1016/j.jaip.2024.11.004
Lee J-H, Kang S-Y, Yu I, Park KE, Oh J-Y, Lee J-H, et al. Cough response to high-dose inhaled corticosteroids in patients with chronic cough and fractional exhaled nitric oxide levels≥ 25 ppb: a prospective study. Lung. 2024;202(3):275–280. doi:10.1007/s00408-024-00698-y
Morice AH, Menon MS, Mulrennan SA, Everett CF, Wright C, Jackson J, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2007;175(4):312–315. doi:10.1164/rccm.200607-892OC
Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9853):1583–1589. doi:10.1016/S0140-6736(12)60776-4
Jeyakumar A, Brickman TM, Haben M. Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy. Laryngoscope. 2006;116(12):2108–2112. doi:10.1097/01.mlg.0000244377.60334.e3
Slinger C, Mehdi SB, Milan SJ, Dodd S, Matthews J, Vyas A, et al. Speech and language therapy for management of chronic cough. Cochrane Database Syst Rev. 2019;7(7):CD013067. doi:10.1002/14651858.CD013067.pub2
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, et al. Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022;399(10328):909–923. doi:10.1016/S0140-6736(21)02348-5
Kum E, Patel M, Diab N, Wahab M, Zeraatkar D, Chu DK, et al. Efficacy and tolerability of gefapixant for treatment of refractory or unexplained chronic cough: a systematic review and dose-response meta-analysis. JAMA. 2023;330(14):1359–1369. doi:10.1001/jama.2023.18035
Smith JA, Birring SS, Blaiss MS, McGarvey L, Morice AH, Sher M, et al. Camlipixant in refractory chronic cough: a phase 2b, randomized, placebo-controlled trial (SOOTHE). Am J Respir Crit Care Med. 2025;211(6):1038–1048. doi:10.1164/rccm.202409-1752OC
Satia I, Mazzone SB. Camlipixant: a new hope for refractory chronic cough? Am J Respir Crit Care Med. 2025;211(6):908–910. doi:10.1164/rccm.202503-0636ED
Maher TM, Avram C, Bortey E, Hart SP, Hirani N, Molyneux PL, et al. Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis. NEJM Evid. 2023;2(8):EVIDoa2300083. doi:10.1056/EVIDoa2300083
